Erasca Inc (ERAS) is a Healthcare · Biotechnology company listed on NASDAQ. Price $15.04 (-1.96%), Market cap $3.18B, 52-week low–high $1.08 ~ $22.47.
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develo
Financial statements, price targets, institutional (13F) holdings and related news for Erasca Inc are updated in real time on BlackAll Trade.
Erasca Inc trades at $15.04 (-1.96%). Real-time quotes and charts are available on BlackAll Trade.
Erasca Inc has a market cap of about $3.18B.
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pi